Monitor the execution of the €30 million share buyback program and its impact on capital allocation, while watching for continued margin expansion in the Materialise Medical segment as a key driver of future profitability.
Price Chart
Executive Summary
Materialise NV reported flat revenue growth of 0.3% in 2025, driven by a 15.4% increase in its high-margin Medical segment, offset by declines in its Software and Manufacturing segments. The company completed an Euronext Brussels listing and authorized a €30 million share buyback, while successfully remediating prior internal control weaknesses. Despite a 42% decline in net profit, Adjusted EBITDA grew 2.8% to $32.4 million, reflecting strong operational execution in its core medical business.
Key Facts
- Revenue increased 0.3% YoY to $267.6 million in 2025, with Materialise Medical segment revenue up 15.4% to $134.2 million
- Net profit declined 42.4% to $7.7 million, but Adjusted EBITDA increased 2.8% to $32.4 million
- Gross profit margin improved to 57.1% from 56.5% in 2024
- Completed Euronext Brussels listing on November 20, 2025, complementing Nasdaq listing
- Authorized €30 million share buyback program on November 14, 2025, with recent purchases reported in 6-K filings
- Successfully remediated material weaknesses in internal controls over financial reporting
Financial Impact
Revenue growth of 0.3% with significant margin expansion in the Medical segment (Adjusted EBITDA margin increased to 32.0% from 30.6%)
Risk Factors
- Revenue decline in Materialise Manufacturing segment (-13.2%) and Software segment (-6.8%)
- Ongoing macroeconomic headwinds and inflation pressures
- Continued operational challenges from the Ukraine conflict
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001104659-26-047671 |
| Document: mtls-20251231xex2d3.htm | 0001104659-26-047671 |
| Document: mtls-20251231xex11d1.htm | 0001104659-26-047671 |
| Document: mtls-20251231xex8d1.htm | 0001104659-26-047671 |
| Document: mtls-20251231xex12d1.htm | 0001104659-26-047671 |
| Document: mtls-20251231xex12d2.htm | 0001104659-26-047671 |
| Document: mtls-20251231xex13d1.htm | 0001104659-26-047671 |
| Document: mtls-20251231xex13d2.htm | 0001104659-26-047671 |
| Document: mtls-20251231xex23d1.htm | 0001104659-26-047671 |
| Document: 0001104659-26-047671-index-headers.html | 0001104659-26-047671 |
| Document: 0001104659-26-047671-index.html | 0001104659-26-047671 |
| Document: 0001104659-26-047671.txt | 0001104659-26-047671 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 6-K | $8.21 | awaiting T+20 | — | $8.67 (+5.60%) |
Oct 13, 2026 12d ago | 6-K | $8.13 | awaiting T+20 | — | $8.67 (+6.64%) |
Oct 5, 2026 20d ago | 6-K | $8.56 | awaiting T+20 | — | $8.67 (+1.29%) |
Sep 8, 2026 6w ago | 6-K | $7.46 $8.50 | ▲ +13.94% | ▲ +11.74% | $8.67 (+16.22%) |
Aug 28, 2026 8w ago | 6-K | $7.21 $8.75 | ▲ +21.36% | ▲ +21.73% | $8.67 (+20.25%) |
Jul 20, 2026 13w ago | 6-K | $6.60 $6.69 | ▲ +1.36% | ▼ −1.20% | $8.67 (+31.36%) |
Jul 13, 2026 14w ago | 6-K | $6.77 $6.87 | ▲ +1.48% | ▼ −1.01% | $8.67 (+28.06%) |
Jul 6, 2026 15w ago | 6-K | $7.04 $6.51 | ▼ −7.53% | ▼ −8.86% | $8.67 (+23.15%) |
Jun 29, 2026 16w ago | 6-K | $7.43 $6.44 | ▼ −13.32% | ▼ −12.30% | $8.67 (+16.69%) |
Jun 22, 2026 17w ago | 6-K | $6.51 $6.56 | ▲ +0.77% | ▼ −0.39% | $8.67 (+33.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers